Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN LEE KITCHENS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841637477
CMS profile
1860929
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$25,208.25

85 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN LEE KITCHENS

NPI 1841637477 · CMS profile ID 1860929

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841637477?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN LEE KITCHENS, NPI 1841637477, CMS profile ID 1860929. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841637477?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BENJAMIN LEE KITCHENS, NPI 1841637477, CMS profile ID 1860929. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841637477?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BENJAMIN LEE KITCHENS, NPI 1841637477, CMS profile ID 1860929, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–85 of 85 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1841637477?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

85 matching records · $25,208.25 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 85 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–85 of 85.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Seagen Inc. $23.9906/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995652589 CMS
ABBVIE INC. $5.8306/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997659759 CMS
Janssen Biotech, Inc. $18.1006/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988748243 CMS
Blueprint Medicines Corporation $19.8506/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051264915 CMS
Astellas Pharma US Inc $22.1505/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034107687 CMS
Janssen Biotech, Inc. $22.8105/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988748247 CMS
Regeneron Healthcare Solutions, Inc. $19.2205/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999253191 CMS
Merck Sharp & Dohme LLC $27.2205/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048720923 CMS
Pharmacosmos Therapeutics Inc. $115.4205/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046253891 CMS
Foundation Medicine, Inc. $16.6405/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058783961 CMS
MorphoSys, US Inc. $15.2004/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060328969 CMS
Astellas Pharma US Inc $14.4904/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034059011 CMS
SOBI, INC $23.1704/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038088507 CMS
Bayer Healthcare Pharmaceuticals Inc. $22.3604/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000516519 CMS
Astellas Pharma US Inc $5.1804/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034035891 CMS
Foundation Medicine, Inc. $25.6403/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058783957 CMS
Blueprint Medicines Corporation $20.0803/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051264839 CMS
Novartis Pharmaceuticals Corporation $20.0203/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992022337 CMS
ABBVIE INC. $16.9003/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997659757 CMS
Seagen Inc. $22.1203/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995652407 CMS
Incyte Corporation $21.9603/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044690473 CMS
Eisai Inc. $20.2703/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023303505 CMS
Jazz Pharmaceuticals Inc. $24.1403/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059097043 CMS
Merck Sharp & Dohme LLC $22.4103/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048273393 CMS
ABBVIE INC. $19.0802/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997659755 CMS
ABBVIE INC. $8.5702/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997659753 CMS
Bayer Healthcare Pharmaceuticals Inc. $29.1002/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000526427 CMS
Pharmacyclics LLC, An AbbVie Company $26.4802/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288773 CMS
ABBVIE INC. $19.5202/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997659751 CMS
Ipsen Biopharmaceuticals, Inc $131.3301/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045454083 CMS
ABBVIE INC. $9.5001/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997659749 CMS
Karyopharm Therapeutics Inc. $20.0401/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056897777 CMS
Eisai Inc. $20.4101/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023303507 CMS
PFIZER INC. $17.1101/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050662523 CMS
Foundation Medicine, Inc. $18.3401/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058783949 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $880.63 36
PY2020 $1,099.52 22
PY2021 $853.05 31
PY2022 $800.27 28
PY2023 $25,208.25 85
PY2024 $63,929.86 121
PY2025 $84,261.37 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $123,375.00 46
PY2024 Principal investigator $83,071.00 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744656
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742285
Principal investigator 1 Genentech, Inc. $2,800.00 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681170
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744654
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742283
Principal investigator 1 Genentech, Inc. $2,800.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211681078
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 11/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742281
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744652
Principal investigator 1 Genentech, Inc. $2,800.00 10/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680911
Principal investigator 1 Genentech, Inc. $2,800.00 10/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680931
Principal investigator 1 Genentech, Inc. $2,800.00 10/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211681016
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742279
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744632
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 09/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742277
Principal investigator 1 Genentech, Inc. $2,800.00 09/12/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680741
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744634
Principal investigator 1 Genentech, Inc. $2,800.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680287
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742275
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744636
Principal investigator 1 Genentech, Inc. $2,500.00 07/21/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675868
Principal investigator 1 Genentech, Inc. $2,800.00 07/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680425
Principal investigator 1 Genentech, Inc. $2,800.00 07/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680561
Principal investigator 1 Genentech, Inc. $2,800.00 07/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680591
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744638
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742273
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744640
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742269
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742271
Principal investigator 1 Genentech, Inc. $2,800.00 05/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680239
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $975.00 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744642
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744644
Principal investigator 1 Genentech, Inc. $2,500.00 04/23/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675825
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742261
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742263
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744646
Principal investigator 1 Genentech, Inc. $4,500.00 03/26/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675792
Principal investigator 1 Genentech, Inc. $2,800.00 03/12/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211679911
Principal investigator 1 ABBVIE INC. $19,000.00 03/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - DALLAS - WORTH STREET
M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202459684
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744648
Principal investigator 1 Genentech, Inc. $2,800.00 02/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211679945
Principal investigator 1 Genentech, Inc. $2,500.00 02/14/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675733
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742265
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742267
Principal investigator 1 Genentech, Inc. $2,500.00 02/04/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675756
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 01/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744650
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742259